Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $52.50 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Puma Biotechnology Stock Performance

PBYI opened at $2.89 on Tuesday. The firm has a market capitalization of $141.86 million, a P/E ratio of 6.02 and a beta of 1.09. The stock’s 50 day moving average price is $3.00 and its two-hundred day moving average price is $2.87. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a 12-month low of $2.22 and a 12-month high of $7.15.

Analyst Ratings Changes

PBYI has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Insiders Place Their Bets

In related news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares in the company, valued at $343,195.65. This trade represents a 7.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the transaction, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.